High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting. Cancer Biol Ther 2022 Dec 31;23(1):1-6
Date
09/29/2022Pubmed ID
36171565Pubmed Central ID
PMC9542347DOI
10.1080/15384047.2022.2128608Scopus ID
2-s2.0-85138956161 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications - "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.
Author List
Joshi RS, Boichard A, Adashek JJ, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorHigh-Throughput Nucleotide Sequencing
Humans
Mutation
Neoplasms
Tumor Burden
Tumor Suppressor Protein p53